Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tributyrin for Cognitive Impairment in Parkinson's Disease
NCT07154511Phase 2Recruiting
- Start
- Nov 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tributyrin in Parkinson's disease (PD), Parkinson's disease dementia (PDD). Started Nov 2025; status: recruiting.
02
Drugs
tributyrin
03
Conditions
Parkinson's disease (PD)Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on NCT07154511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07154511.